Related Experiment Videos
Elevated lipid peroxide levels in platelets of chronic ischemic heart disease patients
Insights
Platelets in chronic ischemic heart disease patients show higher lipid peroxide levels. Aspirin treatment normalizes these levels, suggesting a cyclooxygenase-dependent mechanism and a potential risk factor for atherosclerosis.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Biochemistry
Background:
- Chronic ischemic heart disease (CHD) is associated with increased cardiovascular risk.
- Platelet activation and lipid peroxidation are implicated in atherosclerosis development.
Purpose of the Study:
- To investigate platelet lipid peroxide production in patients with chronic ischemic heart disease (CHD).
- To explore the role of cyclooxygenase in enhanced platelet activity in CHD.
- To assess the effect of aspirin on platelet lipid peroxide levels in CHD patients.
Main Methods:
- Measurement of platelet malondialdehyde-like material (MDA-LM) content.
- Stimulation of platelets using physical methods and N-ethylmaleimide (NEM).
- Comparison between CHD patients and healthy controls.
- Evaluation of aspirin treatment effects in vivo.
Main Results:
- Significantly higher MDA-LM content was observed in CHD platelets compared to controls after stimulation.
- Aspirin treatment (1 gr/day) abolished the difference in MDA-LM content between CHD patients and controls.
- Enhanced lipid peroxide production in CHD platelets appears to be cyclooxygenase-dependent.
Conclusions:
- Platelets from CHD patients exhibit increased lipid peroxide production via a cyclooxygenase-dependent pathway.
- This enhanced platelet activity may represent a novel platelet-dependent risk factor for atherosclerosis in CHD.
- Aspirin effectively mitigates this platelet abnormality in CHD patients.
Abstract:
A significantly higher platelet malondialdehyde-like material (MDA--LM) content after physical and N-ethylmaleimide (NEM) stimulation is found in chronic ischemic heart disease (CHD) patients when compared to the control group. In subjects under aspirin treatment "in vivo" (1 gr/day) no difference is found between CHD and control group. It is suggested that the enhanced amount of lipid peroxides in CHD platelets is produced by a cyclooxygenase-dependent mechanism. This enhanced platelet lipid peroxide production in CHD may be another platelet-dependent risk factor for atherosclerosis in these patients.